The invention relates to a method for inducing human cholangiocyte differentiation of progenitor cells called hepatoblasts. More specifically, the invention relates to a method for differentiating hepatoblasts to cholangiocytes by culturing said hepatoblasts with a particular medium having interleukin-6 (IL-6) activity. The differentiation method can specifically induce cholangiocyte dilferentiation from hepatoblasts, and the human cholangiocytes differentiated according to the invention may be useful for drug discovery for treatment of cholangiopathies and bioengineered livers.

The invention relates to a method for inducing human cholangiocyte differentiation of progenitor cells called hepatoblasts. More specifically, the invention relates to a method for differentiating hepatoblasts to cholangiocytes by culturing said hepatoblasts with a particular medium having interleukin-6 (IL-6) activity. The differentiation method can specifically induce cholangiocyte differentiation from hepatoblasts, and the human cholangiocytes differentiated according to the invention may be useful for drug discovery for treatment of cholangiopathies and bioengineered livers.

The present invention relates to an in vitro culture of haematopoietic cells, wherein said haematopoietic cells differentiate to form granulocytes characterised by the ability to kill cancer cells. The invention also relates to said granulocytes, methods for identifying said haematopoietic cells and granulocytes, compositions and kits comprising the same, as well as uses of the same for treating cancer.

The presently disclosed subject matter provides for in vitro methods of inducing differentiation of stem cells (e.g., human stem cells) into somatotrophs, and differentiated cells generated by such methods. The presently disclosed subject matter also provides for uses of such cells for treating growth hormone deficiency.

Provided are in-vitro methods and devices for sustaining a synchronized circadian rhythm in cells of a cell culture by exposing the cells to a continuous flow of medium and to at least two stimuli provided in an oscillating manner with a periodicity of 244 hours, wherein a first stimulus and a second stimulus of said at least two stimuli are distinct, wherein said first stimulus is provided in a first time period and reaches a first peak in a first peak time period, and wherein a second stimulus is provided in a second time period and reaches a second peak in a second peak time period, and wherein an interval between end of time period of said first peak and beginning of said time period of said second peak is at least about 2 hours.

Provided are in-vitro methods and devices for sustaining a synchronized circadian rhythm in cells of a cell culture by exposing the cells to a continuous flow of medium and to at least two stimuli provided in an oscillating manner with a periodicity of 244 hours, wherein a first stimulus and a second stimulus of said at least two stimuli are distinct, wherein said first stimulus is provided in a first time period and reaches a first peak in a first peak time period, and wherein a second stimulus is provided in a second time period and reaches a second peak in a second peak time period, and wherein an interval between end of time period of said first peak and beginning of said time period of said second peak is at least about 2 hours.

The present invention relates to an in vitro culture of haematopoietic cells, wherein said haematopoietic cells differentiate to form granulocytes characterised by the ability to kill cancer cells. The invention also relates to said granulocytes, methods for identifying said haematopoietic cells and granulocytes, compositions and kits comprising the same, as well as uses of the same for treating cancer.

The present invention relates to an in vitro culture of haematopoietic cells, wherein said haematopoietic cells differentiate to form granulocytes characterised by the ability to kill cancer cells. The invention also relates to said granulocytes, methods for identifying said haematopoietic cells and granulocytes, compositions and kits comprising the same, as well as uses of the same for treating cancer.

The present invention relates to an in vitro culture of haematopoietic cells, wherein the haematopoietic cells differentiate to form granulocytes characterised by the ability to kill cancer cells. The invention also relates to the granulocytes, methods for identifying the haematopoietic cells and granulocytes, compositions and kits comprising the same, as well as uses of the same for treating cancer.

The invention relates to placenta-derived matrix, methods of preparing, and methods of use thereof. The invention also relates to methods of culturing cells, delivering cells, promoting differentiation of stem cells or tissue-specific progenitor cells, and repairing, replacing, regenerating, filling, reducing or inhibiting scarring of defects using the same. The invention further relates to methods of coating placenta-derived matrix on a surface or injecting the placenta-derived matrix into a site of interest.